Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

被引:5
|
作者
da Silva, Fernanda Cardoso [1 ]
Brandao, Douglas Cardoso [1 ]
Ferreira, Everton Allan [2 ]
Siqueira, Raoni Pais [1 ]
Ferreira, Helen Soares Valenca [1 ]
Da Silva Filho, Ademar Alves [2 ]
Araujo, Thaise Goncalves [1 ,3 ]
机构
[1] Univ Fed Uberlandia, Inst Biotechnol, Lab Genet & Biotechnol, BR-38700002 Patos De Minas, MG, Brazil
[2] Univ Fed Juiz de Fora, Fac Pharm, Dept Pharmaceut Sci, BR-36036900 Juiz De Fora, MG, Brazil
[3] Univ Fed Uberlandia, Inst Biotechnol, Lab Nanobiotechnol Prof Dr Luiz Ricardo Goulart Fi, BR-38405302 Uberlandia, MG, Brazil
关键词
breast cancer; hormone therapy; natural products; resistance; CELL-CYCLE ARREST; ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE THERAPY RESISTANCE; NF-KAPPA-B; GROWTH-FACTOR; TUMOR-GROWTH; IN-VITRO; MAMMARY-GLAND; UP-REGULATION; MCF-7; CELLS;
D O I
10.3390/ph16101466
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies.
引用
收藏
页数:40
相关论文
共 50 条
  • [1] The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer
    Ke, Danny Yu Jia
    El-Sahli, Sara
    Wang, Lisheng
    CURRENT CANCER DRUG TARGETS, 2022, 22 (05) : 388 - 403
  • [2] MODULATING THE P 53-MDM2 PATHWAY: THE THERAPEUTIC POTENTIAL OF NATURAL COMPOUNDS IN CANCER TREATMENT
    Ramli, Iman
    Cheriet, Thamere
    Posadino, Anna Maria
    Giordo, Roberta
    Fenu, Grazia
    Nwachukwu, Kingsley Chukwuemeka
    Oyewole, Oluwafemi Adebayo
    Adetunji, Charles Oluwaseun
    Calina, Daniela
    Sharifi-Rad, Javad
    Pintus, Gianfranco
    EXCLI JOURNAL, 2024, 23 : 1397 - 1439
  • [3] Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
    Malayil, Anisha S.
    Poothaadammal, Asifa K.
    Narayanankutty, Arunaksharan
    CURRENT DRUG TARGETS, 2021, 22 (11) : 1255 - 1271
  • [4] Effect of Natural Polyphenols on Breast Cancer Chemoprevention and Treatment
    Sichetti, Marzia
    Giuseffi, Martina
    Giglio, Eugenia
    Marino, Graziella
    Mecca, Marisabel
    MOLECULAR NUTRITION & FOOD RESEARCH, 2025,
  • [5] Dietary Natural Products for Prevention and Treatment of Breast Cancer
    Li, Ya
    Li, Sha
    Meng, Xiao
    Gan, Ren-You
    Zhang, Jiao-Jiao
    Li, Hua-Bin
    NUTRIENTS, 2017, 9 (07)
  • [6] Delivery of natural phenolic compounds for the potential treatment of lung cancer
    Muller, Ashley G.
    Sarker, Satyajit D.
    Saleem, Imran Y.
    Hutcheon, Gillian A.
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 27 (01) : 433 - 449
  • [7] Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer
    Lau, Tsz-Ying
    Kwan, Hiu-Yee
    MARINE DRUGS, 2022, 20 (06)
  • [8] Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
    Shanmugam, Muthu K.
    Warrier, Sudha
    Kumar, Alan P.
    Sethi, Gautam
    Arfuso, Frank
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (06) : 503 - 519
  • [9] Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways
    Wang, Mingchuan
    Liu, Xianjun
    Chen, Tong
    Cheng, Xianbin
    Xiao, Huijie
    Meng, Xianglong
    Jiang, Yang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer
    Ciruelos, Eva
    Cortes-Funes, Hernan
    Ghanem, Ismael
    Manso, Luis
    Arteaga, Carlos
    ANTI-CANCER DRUGS, 2013, 24 (08) : 769 - 780